

This is the author's final, peer-reviewed manuscript as accepted for publication. The publisher-formatted version may be available through the publisher's web site or your institution's library.

## **NleB, a bacterial effector with glycosyltransferase activity targets GADPH function to inhibit NF- $\kappa$ B activation**

Xiaofei Gao, Xiaogang Wang, Thanh H. Pham, Leigh Ann Feuerbacher, Marie-Luise Lubos, Minzhao Huang, Rachel Olsen, Arcady Mushegian, Chad Slawson, and Philip R. Hardwidge

### **How to cite this manuscript**

If you make reference to this version of the manuscript, use the following information:

Gao, X., Wang, X., Pham, T. H., Feuerbacher, L. A., Lubos, M.-L., Huang, M., . . . Hardwidge, P. R. (2013). NleB, a bacterial effector with glycosyltransferase activity targets GADPH function to inhibit NF- $\kappa$ B activation. Retrieved from <http://krex.ksu.edu>

### **Published Version Information**

**Citation:** Gao, X., Wang, X., Pham, T. H., Feuerbacher, L. A., Lubos, M.-L., Huang, M., . . . Hardwidge, P. R. (2013). NleB, a bacterial effector with glycosyltransferase activity targets GADPH function to inhibit NF- $\kappa$ B activation. *Cell Host & Microbe*, 13(1), 87-99.

**Copyright:** Copyright © 2013 Elsevier Inc.

**Digital Object Identifier (DOI):** doi:10.1016/j.chom.2012.11.010

**Publisher's Link:** <http://www.sciencedirect.com/science/article/pii/S1931312812004246>

This item was retrieved from the K-State Research Exchange (K-REx), the institutional repository of Kansas State University. K-REx is available at <http://krex.ksu.edu>

**NleB, a bacterial effector with  
glycosyltransferase activity targets GAPDH  
function to inhibit NF- $\kappa$ B activation**

Xiaofei Gao<sup>1</sup>, Xiaogang Wang<sup>1</sup>, Thanh H. Pham<sup>1,2</sup>, Leigh Ann Feuerbacher<sup>1,2</sup>, Marie-Luise Lubos<sup>3</sup>, Minzhao Huang<sup>1</sup>, Rachel Olsen<sup>1</sup>, Arcady Mushegian<sup>1,4</sup>, Chad Slawson<sup>1</sup>, and Philip R. Hardwidge<sup>1,2\*</sup>

1) University of Kansas Medical Center, Kansas City, KS, 66160

2) College of Veterinary Medicine, Kansas State University, Manhattan, KS, 66506

3) Institute of Infectiology, ZMBE, University of Münster, 48149 Münster, Germany

4) Stowers Institute for Medical Research, 1000 E 50<sup>th</sup> St, Kansas City MO 64110

\*Correspondence to: Philip R. Hardwidge: [hardwidg@gmail.com](mailto:hardwidg@gmail.com); Phone: 785-532-2506; Fax: 785-532-4851

**Running Title:** NleB glycosylates GAPDH to inhibit TRAF2/NF- $\kappa$ B

## Summary.

Modulation of NF- $\kappa$ B-dependent responses is critical to the success of attaching/effacing (A/E) human pathogenic *E. coli* (EPEC and EHEC) and the natural mouse pathogen *Citrobacter rodentium*. NleB, a highly conserved type III secretion system effector of A/E pathogens, suppresses NF- $\kappa$ B activation, but the underlying mechanisms are unknown. We identified the mammalian glycolysis enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an NleB interacting protein. Further, we discovered that GAPDH interacts with the TNF receptor associated factor 2 (TRAF2), a protein required for TNF- $\alpha$ -mediated NF- $\kappa$ B activation, and regulates TRAF2 polyubiquitination. During infection, NleB functions as a translocated *N*-acetyl-D-glucosamine (O-GlcNAc) transferase that modifies GAPDH. NleB-mediated GAPDH O-GlcNAcylation disrupts the TRAF2-GAPDH interaction to suppress TRAF2 polyubiquitination and NF- $\kappa$ B activation. Eliminating NleB O-GlcNAcylation activity attenuates *C. rodentium* colonization of mice. These data identify GAPDH as a TRAF2 signaling cofactor and reveal a virulence strategy employed by A/E pathogens to inhibit NF- $\kappa$ B dependent host innate immune responses.

## Highlights.

The glycolysis enzyme GAPDH interacts with the TNF receptor associated factor, TRAF2

The *C. rodentium* and *E. coli* virulence effector NleB binds GAPDH

NleB uses its *N*-acetyl-D-glucosamine (O-GlcNAc) transferase activity to modify GAPDH

GAPDH O-GlcNAcylation disrupts TRAF2-GAPDH complexes and attenuates NF- $\kappa$ B signaling

## Introduction.

Enterohemorrhagic *E. coli* (EHEC) are attaching/effacing (A/E) pathogens that are especially detrimental to human health because they cause hemorrhagic colitis and a type of renal failure (hemolytic uremic syndrome; HUS) for which therapy is limited. A related *E. coli* virotype, enteropathogenic *E. coli* (EPEC), is an important cause of infantile diarrhea. These human pathogens, as well as *Citrobacter rodentium*, a mouse pathogen that shares virulence strategies with *E. coli* (Deng et al., 2003), translocate virulence proteins (effectors) into intestinal epithelial cells using a type III secretion system (T3SS) to subvert the activity of various cell functions (Dean and Kenny, 2009).

*E. coli* and *C. rodentium* T3SS effectors modulate the innate immune system, including host responses regulated by the transcription factor NF- $\kappa$ B, via several different mechanisms (Rahman and McFadden, 2011). The NleB effector is highly conserved among the A/E pathogens (Kelly et al., 2006). NleB-deficient *C. rodentium* do not cause mortality (Wickham et al., 2007) or significant colonic hyperplasia (Kelly et al., 2006) in mice. These bacteria show markedly reduced colonization, as compared with wild-type (WT) *C. rodentium*, indicating the importance of NleB to *C. rodentium* virulence. NleB is associated with human EHEC outbreaks and the subsequent development of HUS (Wickham et al., 2006). The presence of NleB in atypical EPEC strains is associated with diarrheal disease (Bugarel et al., 2010). Thus, NleB plays an important role in the virulence of A/E pathogens. Two recent studies determined that NleB suppresses NF- $\kappa$ B activation (Nadler et al., 2010, Newton et al., 2010).

Here, we characterize a mechanism by which NleB inhibits NF- $\kappa$ B signaling. NleB functions as a translocated *N*-acetyl-D-glucosamine (O-GlcNAc)-transferase that modifies the mammalian glycolysis enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH). We provide evidence that GAPDH is a co-activator of the TNF receptor associated factor 2 (TRAF2) and that NleB-mediated GAPDH O-GlcNAcylation inhibits both TRAF2 activation and downstream NF- $\kappa$ B signaling.

## Results.

**NleB inhibits NF- $\kappa$ B activation by inhibiting TRAF2 polyubiquitination.** WT *C. rodentium* colonized C57BL/6J mice to a greater magnitude than a strain bearing an isogenic deletion of NleB ( $\Delta nleB$ ; **Fig. S1A**). Complementing  $\Delta nleB$  *C. rodentium* with a FLAG-tagged NleB expression plasmid ( $\Delta nleB/pnleB$ ) restored bacterial colonization to nearly WT levels. WT *C. rodentium* was shed in mouse feces in greater numbers over the duration of infection, as compared with  $\Delta nleB$  *C. rodentium* (**Fig. S1B**). TNF serum concentrations were significantly higher in mice infected with WT *C. rodentium*, than in mice infected with  $\Delta nleB$  (**Fig. 1A**), indicating that NleB contributes to bacterial-induced host inflammation.

NleB inhibits tumor necrosis factor (TNF)-induced NF- $\kappa$ B activation (Newton et al., 2010, Nadler et al., 2010), but its mechanism of action is not clear. We transfected HeLa cells with NleB-HA, stimulated these cells with TNF, and subsequently examined the extent of degradation of the NF- $\kappa$ B inhibitor, I $\kappa$ B $\alpha$ . NleB prevented TNF-induced I $\kappa$ B $\alpha$  degradation, as well as the subsequent translocation of the NF- $\kappa$ B p65 subunit to the nucleus (**Fig. S1C**).

Deleting *nleB* from *C. rodentium* did not significantly alter *nleE* expression, another effector that inhibits NF- $\kappa$ B activation (**Fig. S1D**; (Nadler et al., 2010)]. Both NleB and NleE, when transfected into HeLa cells, inhibited TNF-induced I $\kappa$ B $\alpha$  degradation (**Fig. S1E**). Neither  $\Delta nleB$  nor  $\Delta nleE$  *C. rodentium* prevented I $\kappa$ B $\alpha$  degradation during infection, by contrast to WT *C. rodentium* (**Fig. S1F**), indicating a potential coordinated activity between the effectors during *C. rodentium* infection.

After TNF stimulation, the cytosolic death domain of the TNF receptor-1 (TNFR1) recruits proteins such as the TNFR-associated death domain protein (TRADD), the TNFR associated factor 2 (TRAF2), and the receptor-interacting protein 1 (RIP1) to form complexes that activate the NF- $\kappa$ B pathway (Chen and Goeddel, 2002). During this process, TRAF2, an E3 ubiquitin ligase, becomes polyubiquitinated and activates RIP1 kinase activity. TRAF2 polyubiquitination was induced by TNF in control cells (**Fig. 1B**), whereas cells transfected with NleB-HA exhibited significantly reduced TRAF2 polyubiquitination. The TRAF2 interaction partner TRADD was still recruited to TRAF2 in NleB-transfected cells, suggesting how NleB inhibits TRAF2 polyubiquitination is independent of TRADD.

Bacterial infection induces production of additional TNFR ligands, including RANKL and CD40L (Zheng et al., 2008). These molecules can cause not only TRAF2 polyubiquitination, but also can promote its degradation. We transfected HeLa cells with TRAF2-FLAG and then infected these cells with *C. rodentium* strains that either express or lack NleB. Infecting cells with *C. rodentium*  $\Delta nleB$  induced TRAF2 degradation (**Fig. 1C**), with almost complete degradation of TRAF2 observed after 3 h. By contrast, TRAF2 was stable in cells infected with either WT or  $\Delta nleB/pnleB$  *C. rodentium* (**Fig. 1C**). TRAF2 degradation was mediated by ubiquitination, as  $\Delta nleB$  *C. rodentium* failed to induce the degradation of a TRAF2  $\Delta$ RING mutant (**Fig. 1D**). Treating cells with the 26S proteasome inhibitor MG-132 also stabilized TRAF2 during infection (**Fig. 1E**).

We hypothesized that NleB might target the TRAF2 polyubiquitination normally induced upon TNFR stimulation. TRAF2 polyubiquitination was prevented in cells infected with either WT or  $\Delta nleB/pnleB$  *C. rodentium*, but not  $\Delta nleB$  *C. rodentium* (**Fig. 1E**). NleB also inhibited the ubiquitination of RIP1, a substrate of TRAF2 Ub ligase activity [(Alvarez et al., 2010); **Fig. 1F**]. However, NleB did not directly inhibit TRAF2 self-ubiquitination *in vitro* (**Fig. S1G**). Overall, our data instead suggested that NleB might target an unidentified co-activator(s) of TRAF2 to prevent its polyubiquitination upon either TNFR stimulation or after bacterial infection, subsequently attenuating NF- $\kappa$ B activation.

**NleB interacts with GAPDH.** We did not obtain evidence that NleB interacts with TRAF2 from immunoprecipitation experiments (**Fig. 1B**). We conducted a proteomic screen to identify NleB interaction partner(s). By purified NleB-FLAG (**Fig. 2A**) and used it in affinity column experiments to identify a human protein of ~37 kDa that interacted with NleB (**Fig. 2B**). By using mass spectrometry and immunoblotting affinity-purified cell lysates, we identified this protein as human glyceraldehyde 3-phosphate dehydrogenase (GAPDH; **Fig. 2C-D**), a component of the glycolysis pathway.

GAPDH co-immunoprecipitated ectopically expressed NleB-HA, but not an HA-epitope control (**Fig. 2E**). Infecting HeLa cells with *C. rodentium* strains expressing either NleB or NleC [an effector that also targets the NF- $\kappa$ B pathway; (Pearson et al., 2011)], showed that NleB, but not NleC, immunoprecipitated with GAPDH during *C. rodentium* infection (**Fig. 2F**). We then developed an *in vitro* pulldown assay with purified recombinant proteins. NleB-FLAG, but not NleC-FLAG, binds directly to GAPDH (**Fig. 2G**), as NleB-FLAG was pulled down *in vitro* when mixed with GAPDH.

We quantified the affinity of the NleB-GAPDH interaction *in vitro* by performing ELISAs. NleB-FLAG bound to immobilized GAPDH with an apparent dissociation constant ( $K_d$ ) of  $32 \pm 6 \mu\text{M}$  (**Fig. 2H**). By contrast, NleC-FLAG did not bind GAPDH with significant affinity. We did not detect significant changes in the abundance or in the cytoplasmic localization of GAPDH as a function of expressing NleB (*data not shown*).

Some apoptotic stimuli generate nitric oxide, which subsequently causes GAPDH to be S-nitrosylated on its catalytic cysteine (C150) residue (Hara et al., 2005). We found that both WT and a C150S GAPDH mutant protein bound directly to NleB *in vitro* (**Fig. 2I**). Likewise, treating GAPDH with iodoacetate (IA), a small molecule inhibitor that modifies the GAPDH C150 sulfhydryl moiety and prevents disulfide bond formation (Harrison et al., 2003), at a concentration sufficient to inhibit GAPDH enzyme activity (10  $\mu\text{M}$ ; **Fig. 2J**), did not disrupt the GAPDH-NleB interaction *in vitro* (**Fig. 2K**). NleB binding to GAPDH did not inhibit GAPDH enzyme activity (**Fig. 2J**), either alone, or in concert with IA, indicating the NleB-GAPDH interaction is unlikely to affect host glycolysis directly. Overall, our data suggest that GAPDH is a eukaryotic interaction partner for NleB and this interaction is independent of GAPDH C150.

**GAPDH is required for TNF-induced NF- $\kappa$ B activation.** The role of GAPDH in stress response pathways has been studied previously (Hara et al., 2005). GAPDH participates in NF- $\kappa$ B signaling (Bouwmeester et al., 2004, Mookherjee et al., 2009), but the precise mechanism has not been elucidated. Transfecting siRNAs targeting the GAPDH-3' UTR GAPDH depleted GAPDH abundance by approximately 50 % (**Fig. S2A**), activated multiple stress-induced signaling pathways (**Fig. S2B**), possibly due to the generation of reactive oxygen species (ROS; **Fig. S2C**) and the release of cytochrome *c* from mitochondria (**Fig. S2D**). Complementing GAPDH knockdown cells with either WT or C150S GAPDH-Myc prevented cytochrome *c* release (**Fig. S2D**) and reduced NF- $\kappa$ B pathway activation (**Fig. S2E-F**).

Complementing GAPDH knockdown cells with a GAPDH K160R plasmid, which encodes a form of GAPDH that cannot be acetylated by the p300/CREB binding protein [CBP; (Sen et al., 2008)], did not inhibit TNF-induced I $\kappa$ B $\alpha$  degradation (**Fig. S2E**). The K160 residue is essential for GAPDH binding to p300/CBP in the nucleus, an interaction that subsequently activates downstream apoptotic events. Because initiation of apoptosis typically leads to NF- $\kappa$ B pathway activation (Van Antwerp et al., 1996), we conclude that K160 is not likely to be involved in TNF/NF- $\kappa$ B signaling under the conditions of our assays.

By contrast to WT and K160R GAPDH, complementing GAPDH knockdown cells with GAPDH C150S resulted in a ~30 % reduction in cellular ATP levels (**Fig. S2G**). This ~30 % reduction in [ATP] is not likely to contribute to the attenuation of NF- $\kappa$ B activation, as a larger reduction in [ATP] was observed by inhibiting the rate-limiting glycolytic enzyme, pyruvate kinase, with potassium oxalate (PO; **Fig. S2H**). However, pyruvate kinase inhibition only caused a mild attenuation of TNF-induced NF- $\kappa$ B activation (**Fig. S2I**).

We hypothesized that GAPDH enzyme activity might be required for NF- $\kappa$ B activation after TNF stimulation. Whereas complementation with WT GAPDH only slightly enhanced NF- $\kappa$ B activation, complementation with GAPDH C150S instead significantly attenuated NF- $\kappa$ B activation after TNF treatment (**Fig. 3A**). AP-1 luciferase activity was independent of GAPDH enzyme activity (**Fig. 3B**), suggesting a degree of specificity of GAPDH to the NF- $\kappa$ B pathway. Expressing GAPDH C150S failed to restore TNF-induced IKK $\beta$  phosphorylation in GAPDH knockdown cells (**Fig. 3C**). We concluded that WT GAPDH is required for TNF-induced NF- $\kappa$ B activation.

We used a pharmacological approach to evaluate the role of glycolysis on TNF-induced NF- $\kappa$ B activation. We first pre-treated HeLa cells with IA to inhibit GAPDH and then treated these cells with TNF. While IA targets many other proteins containing reactive cysteines, including deubiquitinating peptidases, a number of other studies have used this reagent to inhibit both GAPDH and glycolysis (Fujiki et al., 2011, Wentzel et al., 2003). We also pre-treated cells with two other drugs that target glycolytic enzymes, either a pyruvate kinase inhibitor, potassium oxalate (PO), or a hexokinase inhibitor, 2-deoxy-D-glucose (2DG). Treating cells with either PO or with 2DG depleted [ATP] to ~20 % of that detected in untreated cells (**Fig. S2H**). By contrast, IA treatment only reduced [ATP] s ~2-fold. However, IA significantly inhibited GAPDH enzyme activity, whereas both 2DG and PO had less impact (**Fig. S2J**).

Following TNF treatment, we conducted gene expression analyses. Our microarray (*data not shown*) and RT-PCR assays (**Fig. S2K**) showed that IA significantly inhibited TNF-induced increases in the expression of numerous NF- $\kappa$ B-regulated genes. By contrast, neither 2DG nor PO significantly reduced the NF- $\kappa$ B-dependent gene expression normally induced by TNF. We reached similar conclusions by studying NF- $\kappa$ B luciferase reporter activation after inhibitor treatment (**Fig. S2I**). By contrast to the NF- $\kappa$ B-regulated genes, the expression of NF- $\kappa$ B-independent genes was not impaired by drug treatment (**Fig. S2K**), again suggesting a

degree of specificity for GAPDH activity in the NF- $\kappa$ B pathway.

Likewise, TNF failed to induce I $\kappa$ B $\alpha$  degradation and IKK $\beta$  phosphorylation in IA-treated cells, but had normal activity in cells treated with either PO or with bromopyruvate (BP), a hexokinase inhibitor (**Fig. S2L**). Both p38 and JNK phosphorylation were unaffected by IA (**Fig. S2L**). These data suggest that GAPDH regulates the NF- $\kappa$ B signaling pathway using a mechanism distinct from its enzymatic role in glycolysis.

**GAPDH binds and activates TRAF2.** TRAF2 is structurally similar to the E3 ligase Siah1, which interacts with GAPDH under stress (Hara et al., 2005). To determine whether GAPDH interacts with TRAF2, we co-transfected TRAF2-FLAG with GAPDH-Myc and then immunoprecipitated TRAF2-FLAG. WT GAPDH was associated with TRAF2 and this interaction was enhanced by TNF (**Fig. 4A**). The association of endogenous GAPDH with TRAF2 was also promoted by TNF (**Fig. 4B**). Using *in vitro* pulldown assays with TRAF2-His, NleB-FLAG, and recombinant GAPDH, we determined that TRAF2 interacts directly with GAPDH, but not with NleB (**Fig. 4C**). GAPDH C150S did not immunoprecipitate with TRAF2 (**Fig. 4A**), suggesting the importance of the C150 residue for the interaction between GAPDH and TRAF2 *in vivo*. TRAF2 bound to WT GAPDH with an apparent  $K_d$  of  $96 \pm 31 \mu\text{M}$  (**Fig. 4D**). TRAF2 did not bind to GAPDH C150S with significant affinity.

We investigated whether the GAPDH-TRAF2 interaction is important for TRAF2 activity in response to TNF. After transfecting GAPDH siRNA and GAPDH-Myc plasmids, we treated cells with TNF and immunoprecipitated TRAF2. TRAF2 polyubiquitination was enhanced in cells expressing WT GAPDH (**Fig. 4E**), whereas TRAF2 polyubiquitination was attenuated in cells either complemented with GAPDH C150S or in cells treated with IA. This phenotype appears to be unrelated to cellular ATP levels, as treating cells with PO (**Fig. 4E**, lane 4), which significantly reduced ATP stores (**Fig. S2H**) did not impair TRAF2 polyubiquitination. Thus, GAPDH binds TRAF2, its recruitment is dependent upon the C150 residue, and the interaction is enhanced by TNF.

**NleB is a glycosyltransferase that O-GlcNAcylates GAPDH.** Analysis of the NleB amino acid sequence using the HHPred/HHSearch package (Soding et al., 2005), revealed that the central region of NleB is significantly similar (p-value  $10^{-7}$ ) to GT-8 family glycosyltransferases. These glycosyltransferases have a conserved sequence and three-dimensional structure, represented by either a canonical or by a modified Rossmann fold. These proteins are also characterized by a DxD catalytic signature, which chelates the divalent cation implicated in catalysis (Liu and Mushegian, 2003). The DxD signature, in the form of DAD tripeptide, is present in all NleB homologs we examined, as well as in the most closely related glycosyltransferases within the GT-8 family, namely the eukaryotic glycogenins (**Fig. S3A**).

Glycogenins are glycosyltransferases that attach glucose to the growing glycogen chain (Lazarus et al., 2011). Multiple sequence alignments indicated the conservation of several beta-strands and connecting  $\alpha$ -helices that form the modified Rossmann fold in the glycogenin structure (**Fig. S3A**). Particularly well conserved are two beta-strands connected by the loop in which the conserved catalytic DxD motif is located, as well as the upstream motif between two alpha-helices that makes direct contacts to the uridine diphosphate (UDP), the dinucleotide substrate of human glycogenin 1.

In eukaryotic cells, O-linked-N-acetylglucosamine (O-GlcNAc) regulates numerous cellular signaling networks, including the NF- $\kappa$ B pathway (Yang et al., 2008), often in opposition with protein phosphorylation. O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) regulate protein O-GlcNAcylation (Hart et al., 2011). OGT catalyzes the transfer of N-acetylglucosamine from UDP-GlcNAc to the hydroxyl oxygen of serine or threonine, whereas OGA removes O-GlcNAc from targeted proteins.

We used an O-GlcNAc *in vitro* labeling assay to determine whether NleB possess glycosyltransferase activity. Alpha-crystallin, which contains a number of amino acids that can be O-GlcNAcylated, was used as a positive control. We incubated purified NleB-FLAG with GAPDH in the presence of UDP-GlcNAc and discovered that NleB-FLAG is capable of O-GlcNAcylating GAPDH (**Fig. 5A**). We confirmed these data by using an antibody (110.6) that specifically recognizes O-GlcNAcylation sites on proteins (**Fig. 5B**). The intensity of NleB-mediated GAPDH O-GlcNAcylation was proportional to the concentration of the sugar nucleotide donor UDP-GlcNAc (**Fig. 5C**).

To investigate whether NleB O-GlcNAcylates GAPDH during bacterial infection, we infected HeLa cells for 3 h with *C. rodentium*. GAPDH O-GlcNAcylation was induced in cells infected with WT *C. rodentium*, but not in cells infected with  $\Delta nleB$  *C. rodentium* (**Fig. 5D**). GAPDH was not O-GlcNAcylated in control cells or in cells treated only with TNF (**Fig. 5E**). However, after transfecting NleB-HA, GAPDH was modified with O-GlcNAc (**Figs. 4E & 5E**). NleB also O-GlcNAcylated GAPDH C150S *in vivo* (**Fig. 4E**) and *in vitro* (**Fig. 5F**), consistent with results suggesting GAPDH C150 is not required for the GAPDH-NleB interaction.

To begin to identify GAPDH O-GlcNAcylation sites, we first considered several GAPDH residues that are modified by cellular enzymes. Although we did not detect OGT in TRAF2-GAPDH complexes (**Fig. 4E**), OGT has been suggested to O-GlcNAcylate GAPDH on T229 (Park et al., 2009). We mutated T229 (T229A) and a neighboring threonine residue, T211 (T211A), to determine if NleB targets them for modification. However, neither mutant differed in NleB-mediated GAPDH O-GlcNAcylation (**Fig. 5F**). GAPDH is phosphorylated by protein kinase B (AKT) on T237, which prevents GAPDH nuclear translocation and suppresses GAPDH-mediated apoptosis (Huang et al., 2011). We also mutated T237 (T237A), as well as the neighboring residues S241 (S241A), T246 (T246A), and T277 (T277A). However, we still did not detect significant changes to NleB-mediated GAPDH O-GlcNAcylation, indicating there may be other or multiple GAPDH residues targeted by NleB (**Fig. 5F**).

To confirm further that NleB is an O-GlcNAc transferase, we mutated the predicted catalytic site <sup>221</sup>DAD<sub>223</sub> of NleB to <sup>221</sup>AAA<sub>223</sub>. The NleB <sup>221</sup>DAD-AAA<sub>223</sub> mutant [hereafter designated NleB(AAA)] failed to O-GlcNAcylate GAPDH proteins either *in vivo* (**Fig. 4E & Fig. 5E**) or *in vitro* (**Fig. 5G**). Expressing an NleB mutant in which the modified Rossmann fold was deleted ( $\Delta$ 202) also abolished the O-GlcNAcylation of GAPDH by NleB (**Fig. 5G**). However, GAPDH, in the presence or absence of NleB and UDP-GlcNAc did not directly inhibit TRAF2 self-ubiquitination *in vitro* (**Fig. S3B**).

O-GlcNAcase catalyzes the cleavage of O-GlcNAc from glycosylated proteins. Treating cells with an O-GlcNAcase inhibitor, thiamet G (TMG), increased total cellular protein O-GlcNAcylation (**Fig. 5E**). We tested whether O-GlcNAcylation of GAPDH by NleB is enhanced by TMG treatment. Although we did not detect any basal GAPDH O-GlcNAcylation in our experimental system, we found that GAPDH O-GlcNAcylation was significantly enhanced by NleB (**Fig. 5E**), and further enhanced after TMG treatment. By contrast, the NleB(AAA) mutant failed to induce GAPDH O-GlcNAcylation, irrespective of TMG. Thus, NleB activity appears to be linked to cellular O-GlcNAc concentrations. These experiments were conducted using ectopic expression of NleB and NleB(AAA) to allow specific analysis of the TNF/TRAF2 pathway, in the absence of other potential inducers generated during bacterial infection (e.g. IL-1 $\beta$ , LPS).

Most proteins that are O-GlcNAcyated by OGT are sensitive to glucose concentrations because this sugar affects the activity of the hexosamine biosynthetic pathway (Hart et al., 2011). In our system, total protein O-GlcNAcylation was decreased in cells cultured in hypoglycemic conditions, as compared with hyperglycemic conditions (**Fig. S3C**). However, the level of GAPDH O-GlcNAcylation mediated by NleB did not change significantly in the different glucose conditions (**Fig. S3D**), indicating that the activity of NleB may be largely insensitive to changes in UDP-GlcNAc concentrations. Taken together, our data suggest that NleB is a translocated glycosyltransferase that modifies host GAPDH with O-GlcNAc.

### **NleB O-GlcNAc transferase activity disrupts the GAPDH-TRAF2 interaction and inhibits NF- $\kappa$ B activity.**

We immobilized TRAF2-His on Ni-NTA agarose and then applied either purified GAPDH or NleB-FLAG  $\pm$  UDP-GlcNAc to assess the binding interactions among these three proteins. More NleB-FLAG was pulled down by GAPDH/TRAF2 in the absence of UDP-GlcNAc than when UDP-GlcNAc was present (**Fig. 6A**). When incubated with NleB and UDP-GlcNAc, only the GAPDH that had dissociated from TRAF2 possesses a significant O-GlcNAcylation signal, as compared with GAPDH still bound to TRAF2 (**Fig. 6B**). We therefore hypothesized that NleB might interact with GAPDH to disrupt the formation of TRAF2-GAPDH complex through its O-GlcNAc transferase activity. Indeed, while WT NleB blocked the association of GAPDH with TRAF2 after TNF treatment, the glycosyltransferase-deficient mutant NleB(AAA) failed to do so (**Fig. 4E**).

GAPDH that had been previously labeled *in vitro* with O-GlcNAc by NleB had significantly lower affinity for TRAF2, as compared with unlabeled GAPDH (**Fig. 6C**), while adding excess UDP-GlcNAc to the ELISA had no discernible impact on TRAF2-GAPDH affinity (**Fig. 6C**). Thus, the glycosyltransferase activity of NleB appears to disrupt the TRAF2-GAPDH interaction, as GAPDH O-GlcNAcylation by NleB significantly reduced the affinity between GAPDH and TRAF2 *in vitro* (**Fig. 6**) and prevented their association *in vivo* (**Fig. 4**).

We next examined whether NleB-mediated GAPDH O-GlcNAcylation is essential for NleB to inhibit NF- $\kappa$ B pathway activation. By contrast to WT NleB, NleB(AAA) did not prevent I $\kappa$ B $\alpha$  degradation stimulated by TNF (**Fig. 5E**). NleB $\Delta$ 202 mutant also failed to block I $\kappa$ B $\alpha$  degradation and p65 nuclear translocation (**Fig. 6D**). These data are consistent with our findings that TRAF2 polyubiquitination was not impaired by the glycosyltransferase-deficient mutant NleB(AAA) upon TNF stimulation, by contrast with WT NleB (**Fig. 4D & 5E**).

WT NleB completely abolished TRAF2 polyubiquitination induced by TNF in TMG-treated cells, whereas NleB(AAA) had no impact (**Fig. 5E**, lanes 7 vs. 8). Although TMG treatment alone did not prevent I $\kappa$ B $\alpha$  degradation and NF- $\kappa$ B activation, it stabilized I $\kappa$ B $\alpha$  in the presence of WT NleB, but not in the presence

of NleB(AAA) (**Fig. 5E**). NleB exhibited a more robust inhibition of NF- $\kappa$ B in cells treated with TMG as compared with cells not treated with TMG (**Fig. 6E**). NF- $\kappa$ B activity was promoted by TMG treatment, consistent with previous reports (Kawauchi et al., 2009). Neither NleB nor TMG altered AP-1 activation (**Fig. 6F**), indicating that NleB-mediated GAPDH O-GlcNAcylation is specifically involved in the NF- $\kappa$ B signaling pathway.

To evaluate whether the O-GlcNAc transferase activity of NleB is important to *C. rodentium* virulence, we infected mice with *C. rodentium* strains expressing either WT NleB ( $\Delta nleB/pnleB$ ) or the O-GlcNAc transferase-deficient NleB mutant, NleB(AAA) [ $\Delta nleB/pnleB(AAA)$ ]. Mice infected with  $\Delta nleB/pnleB(AAA)$  *C. rodentium* strain showed a ~100-fold reduction in colonization magnitude after 7 days, as compared with *C. rodentium* expressing WT NleB (**Fig. 6G**). While the reduction in colonization was not as great as compared with the impact of deleting the entire *nleB* gene, this result demonstrated that a major role of *C. rodentium* host colonization mediated by NleB is due to its O-GlcNAc transferase activity.

Consistent with this phenotype, the NleB(AAA) mutant failed to suppress NF- $\kappa$ B activation during *C. rodentium* infection of HeLa cells, as compared with WT and  $\Delta nleB/pnleB$  *C. rodentium*, even in the absence of exogenous TNF (**Fig. 6H**). Over-expressing GAPDH ectopically in cells that were subsequently infected with *C. rodentium* strains expressing NleB was able to restore partially NF- $\kappa$ B luciferase activity (**Fig. 6H**). By contrast, GAPDH over-expression did not increase NF- $\kappa$ B activity in cells infected with  $\Delta nleB$  *C. rodentium*, suggesting a potential saturation of the interaction between GAPDH and endogenous TRAF2. Because GAPDH over-expression also did not significantly increase basal NF- $\kappa$ B activity in uninfected cells, our data suggest that the O-GlcNAc transferase activity of NleB is essential for its ability to inhibit NF- $\kappa$ B activation and to enhance *C. rodentium* colonization and virulence through a mechanism involving the modification of GAPDH (**Fig. 7**). Further, these data suggest that GAPDH might play a role as a general stress sensor by participating in NF- $\kappa$ B signaling.

## Discussion.

Several studies have suggested GAPDH may be involved in regulating innate immunity. GAPDH is enriched with the NF- $\kappa$ B family member c-Rel and with other NF- $\kappa$ B signaling molecules (Bouwmeester et al., 2004). Mookherjee *et al* also predicted that GAPDH interacts with molecules in the NF- $\kappa$ B pathway (Mookherjee et al., 2009). GAPDH binding to TRAF2 was enhanced under stress conditions, similar to the interaction between Siah1 and GAPDH (Hara et al., 2005). Our data suggest that GAPDH may be a co-activator of TRAF2, perhaps acting at an early step in the TNF/NF- $\kappa$ B signaling pathway, before E1 and E2 enzymes are recruited to TRAF2. How GAPDH facilitates TRAF2 polyubiquitination is unknown and will require significant future structure-function experiments. We raise the possibility that there may be a network of factors recruited to TRAF2 upon TNFR stimulation that is important to regulating TRAF2 activation, among these, GAPDH.

While TNF activates the NF- $\kappa$ B, p38, and JNK signaling pathways through TRAF2, the role of TRAF2 ubiquitination is more essential to downstream JNK, than to either p38 or NF- $\kappa$ B signaling (Habelhah et al., 2004), possibly due to the redundant role of TRAF2 and TRAF5 in NF- $\kappa$ B activation (Tada et al., 2001, Yeh et al., 1997). Our data show that GAPDH-mediated TRAF2 ubiquitination is required for NF- $\kappa$ B activation, but not for JNK and p38 activation. GAPDH may catalyze a specific form of TRAF2 ubiquitination or may promote a different modification that somehow enhances the TRAF2 polyubiquitination activity required for downstream NF- $\kappa$ B activation.

We found that the GAPDH C150 residue is essential to the GAPDH-TRAF2 interaction. This is consistent with previous work, which also showed that C150 is involved in the GAPDH activities that are independent of glycolysis (Hara et al., 2005). Although it is not clear how C150 contributes to GAPDH involvement in these processes, this active site residue is redox-sensitive and is often modified under stress conditions.

Various studies have also shown that cellular signaling and protein glycosylation are tightly linked (Wellen and Thompson, 2012). O-GlcNAcylation requires UDP-GlcNAc, the final product of the hexosamine biosynthetic pathway. Evidence that O-GlcNAcylation is important in regulating immune signaling pathways is emerging. Enhanced glucose metabolism induces O-GlcNAcylation of NF- $\kappa$ B components and increases NF- $\kappa$ B activity (Kawauchi et al., 2009, Yang et al., 2008). For example, O-GlcNAcylation of TAB1 after IL-1 $\beta$  stimulation is essential for TAK1 activation and NF- $\kappa$ B activation (Pathak et al., 2012). In agreement with these studies, we found that inhibiting OGA increased NF- $\kappa$ B activity after TNF stimulation.

We showed that GAPDH is O-GlcNAcylated by the T3SS effector NleB, a glycogenin-related glycosyltransferase. O-GlcNAcylated GAPDH fails to interact with TRAF2 *in vivo*. GAPDH O-GlcNAcylation by OGT on T227 has been reported before (Park et al., 2009). However, we did not detect OGT-mediated GAPDH O-GlcNAcylation under our experimental conditions. We are currently identifying NleB-mediated O-GlcNAcylation site(s) on GAPDH to clarify the precise mechanism by which GAPDH functions in the NF- $\kappa$ B signaling pathway.

We have considered the possibility that NleB activity could be somehow coordinated with changes to host cell metabolism associated with infection (Borregaard and Herlin, 1982, Cramer et al., 2003). However, our preliminary efforts to address this complex issue indicated that NleB-mediated GAPDH O-GlcNAcylation is largely insensitive to different glucose concentrations, likely due to the maintenance of relatively high concentrations of UDP-GlcNAc. Therefore, NleB does not appear to share the same mechanism as OGT, which by contrast, is sensitive to glucose concentrations (Hart et al., 2011). However, inhibiting OGA with TMG augmented GAPDH O-GlcNAcylation by NleB, leaving open the possibility that NleB co-ordinately regulates protein O-GlcNAcylation in concert with the mammalian enzymes OGT and OGA.

*Clostridial* toxins glucosylate and inhibit GTPases of the Rho and Ras superfamily (Kelly and LaMont, 2008). *Legionella pneumophila* Lgt proteins glucosylate the eukaryotic elongation factor 1A to block protein synthesis (Belyi et al., 2006). Like NleB, these toxins all belong to GT-A family of glycosyltransferases and contain at least one Rossmann-like fold and the DXD catalytic motif. We have yet to characterize the substrate specificity of NleB and it is possible that NleB may be able to utilize other nucleotide sugars to glucosylate GAPDH. It remains to be determined if NleB interacts with other host proteins, and if so, whether NleB O-GlcNAcylates these proteins. We note that several other proteins detected in GAPDH immunoprecipitates appear to be more heavily O-GlcNAcylated in the presence, than in the absence, of NleB (**Fig. 5D**).

The difference in colonization magnitude between the  $\Delta nleB$  strain and  $\Delta nleB/pnleB(AAA)$  is not unexpected. NleB contains an additional DAD motif in its N-terminus, which could also contribute to the ability of NleB to control TNF-induced NF- $\kappa$ B activity. It will be interesting to examine the contribution of other NleB

functional domains to bacterial virulence. It is also possible that NleB has functions that are independent of its glycosyltransferase activity and its targeting of the NF- $\kappa$ B pathway.

The impact of NleB on NF- $\kappa$ B is tightly linked with its O-GlcNAc transferase activity directed against GAPDH. GAPDH fails to interact with TRAF2 in the presence of NleB, resulting in attenuated TRAF2 polyubiquitination. This is similar to the phenotype of cells expressing GAPDH C150S, which also fails to bind TRAF2 and fails to promote TRAF2 polyubiquitination. Furthermore, the NleB(AAA) mutant is unable to O-GlcNAcylate GAPDH and does not inhibit NF- $\kappa$ B activation. Our discovery that NleB utilizes UDP-GlcNAc to disrupt TRAF2 complex formation represents a mechanism by which enteric pathogens inhibit host innate immunity.

## Experimental procedures.

**Bacterial strains, plasmids, reagents, and oligonucleotides.** Reagents were used according to manufacturer's recommendations and are described in the supplemental information. Bacterial strains, plasmids, and oligonucleotide sequences are also described in supplemental information.

**RNA interference.** Three pmol of scrambled siRNAs or siRNAs directed against GAPDH were transfected into HeLa cells using Lipofectamine 2000. The transfection mixture was replaced with complete growth media after 6 h and cells were incubated for a further 60 h prior to harvest. Knockdown specificity was confirmed using immunoblotting. GAPDH siRNA sense-strand sequences were: UTR-1: 5'-AGCACA<sub>2</sub>GAG<sub>2</sub>A<sub>2</sub>GAGAGAGAC<sub>3</sub>T; UTR-2: 5'-CATGTAC<sub>2</sub>ATCA<sub>2</sub>UA<sub>3</sub>GTAC<sub>3</sub>TG; UTR-3: CTC<sub>2</sub>TCACAGT<sub>2</sub>GC<sub>2</sub>ATGTAGA<sub>3</sub>.

**Affinity columns and protein identification by LC-ESI-MS/MS.** Both affinity column and mass spectrometry experiments were conducted essentially as described before (Gao et al., 2009). Bands excised from protein gels were digested in-gel with trypsin at 37 °C overnight. Spectra were obtained in the positive ion mode with a nano ESI-Q-ToF micro mass spectrometer.

**In vitro pulldown assays.** 1.0 mg of purified NleB-FLAG or NleC-FLAG were immobilized on FLAG M2-conjugated beads and then incubated with 1.0 mg GAPDH for 4 h at 4 °C. Beads were centrifuged and washed three times with 20 mM HEPES, pH 7.9, 150 mM KCl, 0.2 mM EDTA, 0.1 % NP-40, 10 % glycerol, 1.0 mM DTT). SDS-PAGE sample buffer was added and samples were analyzed using immunoblotting.

**O-GlcNAcylation assays.** NleB-FLAG or NleC-FLAG proteins (500 ng) were incubated with 500 ng GAPDH at 4 °C for 18 h ± 1 mM UDP-GlcNAc. O-GlcNAcylated proteins were detected using the Click-iT O-GlcNAc Enzymatic Labeling System (Invitrogen). Alternatively, proteins were incubated in 50 mM Tris-HCl, pH 7.5, 1 mM DTT, 10 mM MnCl<sub>2</sub>, 1 mM UDP-GlcNAc for 4 h at room temperature.

**GAPDH enzyme activity.** GAPDH activity in HeLa cells was measured by using a fluorescence-based assay kit (KDalert™ GAPDH) according to the manufacturer's recommendations. Briefly, 1.0\*10<sup>4</sup> cells were treated ± 10 μM IA for 40'. Cells were resuspended in ice-cold Cell Lysis Buffer and incubated for 20'. Aliquots were transferred to 96-well plates and changes in fluorescence were measured every 4' in a fluorescence plate reader. GAPDH activity was determined through comparison to protein standards. For *in vitro* GAPDH enzymatic activity assays, 0.1 μg GAPDH was pre-incubated with 0.1 μg NleB-FLAG or NleC-FLAG with 1 mM IA and or 0.1 mM UDP-GlcNAc.

**Luciferase assays.** Luciferase assays were conducted as described (Gao et al., 2009). HeLa cells were co-transfected at a ratio of 10:1 (1.0 μg total DNA) with a luciferase reporter construct (NF-κB or AP-1) together with the renilla luciferase pTKRL plasmid, cultured for 48 h, in the presence or absence of TNF. Cells were lysed with passive lysis buffer and lysates were analyzed according to the protocol from Dual-Luciferase Kit. The fold-induction was calculated as [relative FU stimulated]/[relative FU unstimulated] samples. Luciferase assays were performed in triplicate with at least three independently transfected cell populations.

**TRAF2 ubiquitination assay.** Ubiquitination assays were performed using enzymes obtained from Boston Biochem, supplemented with NleB (50 nM), and UDP-GlcNAc (1 mM). His-E1(100 nM), Ubc/Uev1a (100 nM), His-TRAF2 (50 nM), ubiquitin (2 μM), and ATP (2 mM) were incubated in 5 mM MgCl<sub>2</sub>, 50 mM HEPES, pH 7.5, 10 mM NaCl, 1 mM DTT) at 30 °C for 1 h, in the presence or absence of GAPDH (50 nM), NleB (50 nM), and UDP-GlcNAc (1 mM). Reactions were terminated by adding SDS-PAGE loading buffer and boiled at 95 °C for 5'. TRAF2 ubiquitination was determined using immunoblotting with α-ubiquitin antibody.

**ELISAs.** TNF concentrations in mouse sera were measured using a mouse TNF Quantikine ELISA Kit according to the manufacturer's instructions. Protein binding studies were conducted as previously described, (Pham et al., 2012).

**Mouse infections.** All animal experiments were performed according to Institutional Animal Care and Use Committee-approved protocols (Animal Welfare Assurance #A3237-01) and conducted as previously described (Gao et al., 2009).

**Bioinformatics.** Probabilistic searches using profile-Hidden Markov Models were done using the HHPred/HHSearch package (Soding et al., 2005). Multiple sequence alignments were obtained using the PROMALS3D software (Pei et al., 2008), seeded with NleB and their glycogenin-related homologs.

**Statistics.** RT-PCR, luciferase, ELISA, and enzyme activity data were analyzed statistically using one-way ANOVA with Bonferonni's multiple comparison tests. *C. rodentium* colonization data were analyzed using the Kruskal-Wallis test. P values < 0.05 were considered significant.

**Acknowledgments.** The project described was supported by Grant Numbers AI076227 and AI093913 from the National Institute of Allergy and Infectious Diseases (NIAID). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID.

## References.

- ALVAREZ, S. E., HARIKUMAR, K. B., HAIT, N. C., ALLEGOOD, J., STRUB, G. M., KIM, E. Y., MACEYKA, M., JIANG, H., LUO, C., KORDULA, T., MILSTIEN, S. & SPIEGEL, S. 2010. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. *Nature*, 465, 1084-8.
- BELYI, Y., NIGGEWEG, R., OPITZ, B., VOGELSGESANG, M., HIPPENSTIEL, S., WILM, M. & AKTORIES, K. 2006. Legionella pneumophila glucosyltransferase inhibits host elongation factor 1A. *Proc Natl Acad Sci U S A*, 103, 16953-8.
- BORREGAARD, N. & HERLIN, T. 1982. Energy metabolism of human neutrophils during phagocytosis. *J Clin Invest*, 70, 550-7.
- BOUWMEESTER, T., BAUCH, A., RUFFNER, H., ANGRAND, P. O., BERGAMINI, G., CROUGHTON, K., CRUCIAT, C., EBERHARD, D., GAGNEUR, J., GHIDELLI, S., HOPF, C., HUHSE, B., MANGANO, R., MICHON, A. M., SCHIRLE, M., SCHLEGL, J., SCHWAB, M., STEIN, M. A., BAUER, A., CASARI, G., DREWES, G., GAVIN, A. C., JACKSON, D. B., JOBERTY, G., NEUBAUER, G., RICK, J., KUSTER, B. & SUPERTI-FURGA, G. 2004. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. *Nat Cell Biol*, 6, 97-105.
- BUGAREL, M., BEUTIN, L. & FACH, P. 2010. Low-density macroarray targeting non-locus of enterocyte effacement effectors (nle genes) and major virulence factors of Shiga toxin-producing Escherichia coli (STEC): a new approach for molecular risk assessment of STEC isolates. *Appl Environ Microbiol*, 76, 203-11.
- CHEN, G. & GOEDEL, D. V. 2002. TNF-R1 signaling: a beautiful pathway. *Science*, 296, 1634-5.
- CRAMER, T., YAMANISHI, Y., CLAUSEN, B. E., FORSTER, I., PAWLINSKI, R., MACKMAN, N., HAASE, V. H., JAENISCH, R., CORR, M., NIZET, V., FIRESTEIN, G. S., GERBER, H. P., FERRARA, N. & JOHNSON, R. S. 2003. HIF-1alpha is essential for myeloid cell-mediated inflammation. *Cell*, 112, 645-57.
- DEAN, P. & KENNY, B. 2009. The effector repertoire of enteropathogenic E. coli: ganging up on the host cell. *Curr Opin Microbiol*, 12, 101-9.
- DENG, W., VALLANCE, B. A., LI, Y., PUENTE, J. L. & FINLAY, B. B. 2003. Citrobacter rodentium translocated intimin receptor (Tir) is an essential virulence factor needed for actin condensation, intestinal colonization and colonic hyperplasia in mice. *Mol Microbiol*, 48, 95-115.
- FUJIKI, R., HASHIBA, W., SEKINE, H., YOKOYAMA, A., CHIKANISHI, T., ITO, S., IMAI, Y., KIM, J., HE, H. H., IGARASHI, K., KANNO, J., OHTAKE, F., KITAGAWA, H., ROEDER, R. G., BROWN, M. & KATO, S. 2011. GlcNAcylation of histone H2B facilitates its monoubiquitination. *Nature*, 480, 557-60.
- GAO, X., WAN, F., MATEO, K., CALLEGARI, E., WANG, D., DENG, W., PUENTE, J., LI, F., CHAUSSEE, M. S., FINLAY, B. B., LENARDO, M. J. & HARDWIDGE, P. R. 2009. Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. *PLoS Pathog*, 5, e1000708.
- HABELHAH, H., TAKAHASHI, S., CHO, S. G., KADOYA, T., WATANABE, T. & RONAI, Z. 2004. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. *EMBO J*, 23, 322-32.
- HARA, M. R., AGRAWAL, N., KIM, S. F., CASCIO, M. B., FUJIMURO, M., OZEKI, Y., TAKAHASHI, M., CHEAH, J. H., TANKOU, S. K., HESTER, L. D., FERRIS, C. D., HAYWARD, S. D., SNYDER, S. H. & SAWA, A. 2005. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. *Nat Cell Biol*, 7, 665-74.
- HARRISON, G. J., VAN WIJHE, M. H., DE GROOT, B., DIJK, F. J., GUSTAFSON, L. A. & VAN BEEK, J. H. 2003. Glycolytic buffering affects cardiac bioenergetic signaling and contractile reserve similar to creatine kinase. *Am J Physiol Heart Circ Physiol*, 285, H883-90.
- HART, G. W., SLAWSON, C., RAMIREZ-CORREA, G. & LAGERLOF, O. 2011. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. *Annu Rev Biochem*, 80, 825-58.
- HUANG, Q., LAN, F., ZHENG, Z., XIE, F., HAN, J., DONG, L., XIE, Y. & ZHENG, F. 2011. Akt2 kinase suppresses glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-mediated apoptosis in ovarian cancer cells via phosphorylating GAPDH at threonine 237 and decreasing its nuclear translocation. *J Biol Chem*, 286, 42211-20.
- KAWAUCHI, K., ARAKI, K., TOBIUME, K. & TANAKA, N. 2009. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. *Proc Natl Acad Sci U S A*, 106, 3431-6.

- KELLY, C. P. & LAMONT, J. T. 2008. Clostridium difficile--more difficult than ever. *N Engl J Med*, 359, 1932-40.
- KELLY, M., HART, E., MUNDY, R., MARCHES, O., WILES, S., BADEA, L., LUCK, S., TAUSCHEK, M., FRANKEL, G., ROBINS-BROWNE, R. M. & HARTLAND, E. L. 2006. Essential role of the type III secretion system effector NleB in colonization of mice by Citrobacter rodentium. *Infect Immun*, 74, 2328-37.
- LAZARUS, M. B., NAM, Y., JIANG, J., SLIZ, P. & WALKER, S. 2011. Structure of human O-GlcNAc transferase and its complex with a peptide substrate. *Nature*, 469, 564-7.
- LIU, J. & MUSHEGIAN, A. 2003. Three monophyletic superfamilies account for the majority of the known glycosyltransferases. *Protein Science*, 12, 1418-31.
- MOOKHERJEE, N., LIPPERT, D. N., HAMILL, P., FALSAFI, R., NIJNIK, A., KINDRACHUK, J., PISTOLIC, J., GARDY, J., MIRI, P., NASEER, M., FOSTER, L. J. & HANCOCK, R. E. 2009. Intracellular receptor for human host defense peptide LL-37 in monocytes. *J Immunol*, 183, 2688-96.
- NADLER, C., BARUCH, K., KOBI, S., MILLS, E., HAVIV, G., FARAGO, M., ALKALAY, I., BARTFELD, S., MEYER, T. F., BEN-NERIAH, Y. & ROSENSHINE, I. 2010. The type III secretion effector NleE inhibits NF-kappaB activation. *PLoS Pathog*, 6, e1000743.
- NEWTON, H. J., PEARSON, J. S., BADEA, L., KELLY, M., LUCAS, M., HOLLOWAY, G., WAGSTAFF, K. M., DUNSTONE, M. A., SLOAN, J., WHISSTOCK, J. C., KAPER, J. B., ROBINS-BROWNE, R. M., JANS, D. A., FRANKEL, G., PHILLIPS, A. D., COULSON, B. S. & HARTLAND, E. L. 2010. The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. *PLoS Pathog*, 6, e1000898.
- PARK, J., HAN, D., KIM, K., KANG, Y. & KIM, Y. 2009. O-GlcNAcylation disrupts glyceraldehyde-3-phosphate dehydrogenase homo-tetramer formation and mediates its nuclear translocation. *Biochim Biophys Acta*, 1794, 254-62.
- PATHAK, S., BORODKIN, V. S., ALBARBARAWI, O., CAMPBELL, D. G., IBRAHIM, A. & VAN AALTEN, D. M. 2012. O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release. *EMBO J*, 31, 1394-404.
- PEARSON, J. S., RIEDMAIER, P., MARCHES, O., FRANKEL, G. & HARTLAND, E. L. 2011. A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. *Mol Microbiol*, 80, 219-30.
- PEI, J., KIM, B. H. & GRISHIN, N. V. 2008. PROMALS3D: a tool for multiple protein sequence and structure alignments. *Nucleic Acids Res*, 36, 2295-300.
- PHAM, T. H., GAO, X., TSAI, K., OLSEN, R., WAN, F. & HARDWIDGE, P. R. 2012. Functional differences and interactions between the E. coli type III secretion system effectors NleH1 and NleH2. *Infect Immun*.
- RAHMAN, M. M. & MCFADDEN, G. 2011. Modulation of NF-kappaB signalling by microbial pathogens. *Nat Rev Microbiol*, 9, 291-306.
- SEN, N., HARA, M. R., KORNBERG, M. D., CASCIO, M. B., BAE, B. I., SHAHANI, N., THOMAS, B., DAWSON, T. M., DAWSON, V. L., SNYDER, S. H. & SAWA, A. 2008. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. *Nat Cell Biol*, 10, 866-73.
- SODING, J., BIEGERT, A. & LUPAS, A. N. 2005. The HHpred interactive server for protein homology detection and structure prediction. *Nucleic Acids Res*, 33, W244-8.
- TADA, K., OKAZAKI, T., SAKON, S., KOBARAI, T., KUROSAWA, K., YAMAOKA, S., HASHIMOTO, H., MAK, T. W., YAGITA, H., OKUMURA, K., YEH, W. C. & NAKANO, H. 2001. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. *J Biol Chem*, 276, 36530-4.
- VAN ANTWERP, D. J., MARTIN, S. J., KAFRI, T., GREEN, D. R. & VERMA, I. M. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. *Science*, 274, 787-9.
- WELLEN, K. E. & THOMPSON, C. B. 2012. A two-way street: reciprocal regulation of metabolism and signalling. *Nat Rev Mol Cell Biol*, 13, 270-6.
- WENTZEL, P., EJDESJO, A. & ERIKSSON, U. J. 2003. Maternal diabetes in vivo and high glucose in vitro diminish GAPDH activity in rat embryos. *Diabetes*, 52, 1222-8.
- WICKHAM, M. E., LUPP, C., MASCARENHAS, M., VAZQUEZ, A., COOMBES, B. K., BROWN, N. F., COBURN, B. A., DENG, W., PUENTE, J. L., KARMALI, M. A. & FINLAY, B. B. 2006. Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection. *J Infect Dis*, 194, 819-27.

- WICKHAM, M. E., LUPP, C., VAZQUEZ, A., MASCARENHAS, M., COBURN, B., COOMBES, B. K., KARMALI, M. A., PUENTE, J. L., DENG, W. & BRETT FINLAY, B. 2007. *Citrobacter rodentium* virulence in mice associates with bacterial load and the type III effector NleE. *Microbes Infect*, 9, 400-7.
- YANG, W. H., PARK, S. Y., NAM, H. W., KIM DO, H., KANG, J. G., KANG, E. S., KIM, Y. S., LEE, H. C., KIM, K. S. & CHO, J. W. 2008. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. *Proc Natl Acad Sci U S A*, 105, 17345-50.
- YEH, W. C., SHAHINIAN, A., SPEISER, D., KRAUNUS, J., BILLIA, F., WAKEHAM, A., DE LA POMPA, J. L., FERRICK, D., HUM, B., ISCOVE, N., OHASHI, P., ROTHE, M., GOEDDEL, D. V. & MAK, T. W. 1997. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. *Immunity*, 7, 715-25.
- ZHENG, Y., VALDEZ, P. A., DANILENKO, D. M., HU, Y., SA, S. M., GONG, Q., ABBAS, A. R., MODRUSAN, Z., GHILARDI, N., DE SAUVAGE, F. J. & OUYANG, W. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat Med*, 14, 282-9.

## Figure Legends.

**Figure 1, see also Figure S1. NleB inhibits NF- $\kappa$ B activation by preventing TRAF2 polyubiquitination. A.** TNF concentrations (pg/ml; mean  $\pm$  SEM, n = 8) in serum (7 d post-infection) from uninfected mice or mice infected with indicated *C. rodentium* strains. Asterisks indicate significantly different [TNF] as compared with WT infection (one-way ANOVA with Bonferonni's multiple comparison test). **B.** TRAF2-FLAG was co-transfected with NleB-HA and immunoprecipitated using  $\alpha$ -FLAG antibody. Immunoprecipitates were immunoblotted for FLAG, TRADD, ubiquitin, and HA. LC, antibody light chain. **C.** HeLa cells were transfected with TRAF2-FLAG and then infected with *C. rodentium* for 1 or 3 h. TRAF2 and I $\kappa$ B $\alpha$  abundance were analyzed using immunoblotting. **D.** HeLa cells were transfected with either TRAF2-FLAG or  $\Delta$ RING TRAF2 (TRAF2-RM) plasmids and then infected with *C. rodentium* for 3 h. **E.** HeLa cells were transfected with TRAF2-FLAG, pre-treated with 10  $\mu$ M MG-132 for 2 h, and then infected with *C. rodentium*. TRAF2 was immunoprecipitated and polyubiquitination was assessed using immunoblotting. **F.** RIP1 was co-transfected with NleB-HA and immunoprecipitated using  $\alpha$ -RIP1 antibody. Immunoprecipitates were immunoblotted for ubiquitin and RIP1. Data are represented as mean  $\pm$  SEM, n = 3. Asterisks indicate significantly different [RIP1-Ub] as compared with TNF treatment (Bonferonni's).

**Figure 2. NleB binds GAPDH. A.** NleB-FLAG protein purity assessed by Coomassie Blue staining after 12 % SDS-PAGE. **B.** HeLa cell lysates were incubated with purified NleB-FLAG pre-bound to FLAG M2 beads and analyzed by SDS-PAGE. The band indicated with an asterisk was excised and analyzed using mass spectrometry. **C.** GAPDH amino acid sequence. Tryptic peptides identified by mass spectrometry are indicated in bold. **D.** Affinity column samples were analyzed using immunoblotting with  $\alpha$ -GAPDH antibody. **E.** NleB-HA was transfected. GAPDH was immunoprecipitated and immunoblotted for GAPDH and HA. **F.** Immunoprecipitation of GAPDH from HeLa cells by translocated NleB- or NleC-FLAG after *C. rodentium* infection for 0.5, 1 or 3 h. Samples were immunoprecipitated with  $\alpha$ -GAPDH antibody and immunoblotted for FLAG and GAPDH. **G.** FLAG-tagged NleB or NleC were coupled to M2 beads and incubated with GAPDH. Samples were analyzed using IRDye Blue protein staining after electrophoresis through 12 % SDS-PAGE. **H.** ELISA plates were coated with 2  $\mu$ g GAPDH. Coated plates were overlaid with increasing amounts of NleB- or NleC-FLAG. Protein binding was detected using  $\alpha$ -FLAG antibody and 1-Step Ultra TMB-ELISA solution. Absorbance at 450 nm was measured (mean  $\pm$  SEM, n = 4). **I.** *In vitro* pull-down assay for the interaction between GAPDH C150S and NleB. Purified GAPDH- and GAPDH C150S-His proteins were incubated with NleB-FLAG or NleC-FLAG proteins prebound to M2 beads. **J.** GAPDH enzyme inhibition by iodoacetate (IA; mean  $\pm$  SEM, n = 3). Asterisks indicate significantly different GAPDH activity (Bonferonni's). **K.** Impact of IA on GAPDH-NleB binding was measured using *in vitro* pull-down assay. GAPDH was treated with IA and then incubated with NleB-FLAG prebound to M2 beads.

**Figure 3, see also Figure S2. GAPDH is essential for TNF-induced NF- $\kappa$ B activation. A.** NF- $\kappa$ B luciferase activity as a function of GAPDH complementation (mean  $\pm$  SEM, n = 3). Asterisks indicate significantly different luciferase activity between GAPDH WT and C150S complementation (t-test). **B.** AP-1 luciferase activity as a function of GAPDH complementation (mean  $\pm$  SEM, n = 3). **C.** Analysis of IKK $\beta$  phosphorylation and I $\kappa$ B $\alpha$  degradation in GAPDH knockdown cells complemented with WT GAPDH or GAPDH C150S. HeLa cells were co-transfected with GAPDH siRNA, as well as with IKK $\beta$ -FLAG and either WT GAPDH-Myc or GAPDH-C150S-Myc plasmids, and then stimulated with TNF.

**Figure 4. GAPDH interacts with TRAF2. A.** HeLa cells were transfected with TRAF2-FLAG  $\pm$  GAPDH-Myc plasmids, immunoprecipitated using  $\alpha$ -FLAG antibody, and then immunoblotted using  $\alpha$ -Myc antibody. **B.** Experiment was performed as described in panel A, except that endogenous GAPDH association with TRAF2 was monitored using  $\alpha$ -GAPDH antibody. TNF treatment time is indicated. **C.** TRAF2-His protein was coupled to Ni-NTA agarose and incubated with GAPDH and/or NleB-FLAG  $\pm$  1.0 mM UDP-GlcNAc. The bound and flow-through (FT) samples are indicated. **D.** ELISA plates were coated with 2  $\mu$ g of either WT GAPDH or C150S GAPDH. Coated plates were overlaid with increasing amounts of TRAF2. Protein binding was detected using  $\alpha$ -TRAF2 antibody (mean  $\pm$  SEM, n = 4). **E.** HeLa cells were transfected and treated 60 h later with indicated glycolysis enzyme inhibitors. Cell lysates were immunoprecipitated using  $\alpha$ -FLAG antibody to capture TRAF2-FLAG and immunoblotted for ubiquitin and GAPDH-Myc. Additional immunoprecipitations were conducted using  $\alpha$ -Myc antibody to capture GAPDH-Myc and immunoblotted for O-GlcNAc and OGT.

**Figure 5, see also Figure S3. NleB O-GlcNAcylates GAPDH.** **A.** Detection of GAPDH O-GlcNAcylation by NleB using 5-carboxytetramethylrhodamine (TAMRA). **B.** Detection of GAPDH O-GlcNAcylation by NleB using  $\alpha$ -O-GlcNAc antibody (110.6). **C.** GAPDH O-GlcNAcylation as a function of [UDP-GlcNAc]. NleB- or NleC-FLAG was incubated with GAPDH and UDP-GlcNAc. Proteins were analyzed by SDS-PAGE and immunoblotted for the O-GlcNAcylation using  $\alpha$ -GlcNAc antibody. **D.** GAPDH O-GlcNAcylation during bacterial infection. HeLa cells were infected with *C. rodentium* WT or  $\Delta nleB$  for 1 or 3 h. Cell lysates were immunoprecipitated with  $\alpha$ -GAPDH antibody and analyzed for O-GlcNAcylation. Asterisks indicate other proteins detected in GAPDH immunoprecipitates more heavily O-GlcNAcylated in the presence NleB. **E.** NleB(AAA) does not O-GlcNAcylate GAPDH. HeLa cells were co-transfected with NleB, TRAF2, and GAPDH plasmids for 60 h and treated with 20  $\mu$ M TMG for 8 h  $\pm$  TNF (20'). Cell lysates were immunoprecipitated for TRAF2-FLAG or GAPDH-Myc. Cell lysates were also immunoblotted for total protein O-GlcNAcylation. **F.** Purified GAPDH mutant proteins were incubated with NleB-FLAG and UDP-GlcNAc. GAPDH O-GlcNAcylation was analyzed using  $\alpha$ -GlcNAc antibody. **G.** FLAG-NleB WT and mutants were purified and incubated with WT GAPDH. Samples were analyzed using SDS-PAGE and immunoblotted with  $\alpha$ -GlcNAc and  $\alpha$ -GAPDH antibodies.

**Figure 6. NleB O-GlcNAc transferase activity is essential for inhibiting the NF- $\kappa$ B pathway.** **A.** TRAF2-His was coupled to Ni-NTA beads and then incubated with NleB-FLAG and GAPDH. UDP-GlcNAc (1 mM) was added where indicated. Bound and flow-through (FT) proteins were stained with IRDye Blue. **B.** O-GlcNAcylation of free (FT) and TRAF2-associated GAPDH. Samples were immunoblotted using  $\alpha$ -GlcNAc antibody. **C.** ELISA plates were coated with 2  $\mu$ g of either unmodified GAPDH or GAPDH that had been labeled *in vitro* by O-GlcNAc after incubation with NleB and UDP-GlcNAc. Coated plates were overlaid with increasing amounts of TRAF2  $\pm$  100  $\mu$ M UDP-GlcNAc. Protein binding was detected using  $\alpha$ -TRAF2 antibody (mean  $\pm$  SEM, n = 4). **D.** Immunoblotting of I $\kappa$ B $\alpha$  and p65 nuclear translocation in the presence of NleB( $\Delta$ 202). **E.** NF- $\kappa$ B luciferase activity (mean  $\pm$  SEM, n = 4)  $\pm$  NleB and TMG. HeLa cells were co-transfected with luciferase reporters and NleB-HA or control plasmids for 60 h, and treated with TMG for 8 h before treating with TNF for 20'. Asterisks indicate significantly different luciferase activity, t-test. **F.** AP-1 luciferase activity (mean  $\pm$  SEM, n = 4)  $\pm$  NleB and TMG. **G.** Colonization ( $\log_{10}$  CFUs / g colon) of indicated *C. rodentium* strains (7 d post-gavage) in C57BL/6J mice (n = 6-7). Asterisks indicate significantly different colonization magnitude as compared with WT; Kruskal-Wallis test. **H.** NF- $\kappa$ B luciferase activity as a function of *C. rodentium* infection and GAPDH-Myc over-expression (mean  $\pm$  SEM, n = 4). HeLa cells were co-transfected with GAPDH-Myc or Myc-epitope control plasmids with NF- $\kappa$ B luciferase reporter plasmids for 48 h and then infected with the indicated *C. rodentium* strains for 3 h. Asterisks indicate significantly different luciferase activity between GAPDH-Myc or Myc-epitope transfection.

**Figure 7. Working model for the role of GAPDH in the NF- $\kappa$ B signaling pathway and its targeting by NleB to attenuate TRAF2 activation.** After TNF stimulation through TNFR, GAPDH is induced to the TRAF2 complex, promoting TRAF2 polyubiquitination and activating the NF- $\kappa$ B pathway through IKK. Drug treatments and mutagenesis studies show that this recruitment is dependent upon GAPDH enzyme activity. During infection, NleB binds GAPDH and modifies it with O-GlcNAc. O-GlcNAcylated GAPDH is unable to bind TRAF2, reducing downstream NF- $\kappa$ B activation. NleB(AAA) is deficient in O-GlcNAc transferase activity and unable to inhibit GAPDH binding to TRAF2. Whether NleB directly impacts host cell metabolic pathways and the identification of other substrates for its O-GlcNAcylation activity remain to be determined.